PepGen Inc. Reports Unprecedented Splicing Correction in DM1 Patients with PGN-EDODM1 in Phase 1 Trial
Reuters
Sep 25
<a href="https://laohu8.com/S/PEPG">PepGen Inc.</a> Reports Unprecedented Splicing Correction in DM1 Patients with PGN-EDODM1 in Phase 1 Trial
PepGen Inc. announced positive clinical data from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). The results showed a mean splicing correction of 53.7% following a single dose, with all patients in the cohort demonstrating improved splicing. PGN-EDODM1 was generally well-tolerated, with drug-related adverse events reported as mild or moderate. The company stated that these data build upon previously reported results from lower dose cohorts and that data from the first cohort of the FREEDOM2 multiple ascending dose (MAD) study are expected in the first quarter of 2026. A copy of the corporate presentation including these results will be made available on the PepGen investor website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250924280988) on September 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.